首页|基于广义方程评估308nm准分子激光联合司库奇尤单抗治疗对银屑病患者IL-1、IL-1RA的影响

基于广义方程评估308nm准分子激光联合司库奇尤单抗治疗对银屑病患者IL-1、IL-1RA的影响

扫码查看
目的 基于广义估计方程(generalized estimating equations,GEE)评估波长308 nm准分子激光联合司库奇尤单抗对银屑病(psoriasis,PS)的临床疗效及白细胞介素-1(interleukin-1,IL-1)、IL-1 受体拮抗剂(IL-1 receptor antagonist,IL-1RA)的影响.方法 回顾性分析2021年6月至2023年10月,PS患者120例的临床资料,根据治疗方法不同,分为治疗组和对照组.治疗组患者64例,采用波长308 nm准分子激光联合司库奇尤单抗治疗,每周照射1次,共照射8次,连续治疗2个月,照射能量密度平均为(380±21.76)mJ/cm2.对照组患者56例,仅采用司库奇尤单抗治疗,1次/周,每次300 mg,连续治疗2个月.两组患者治疗1个月后、治疗2个月后,采用GEE评估两组患者IL-1、IL-1RA及皮损面积和严重程度指数(psoriasis area and severity index,PASI)的改善情况.治疗前、治疗1个月后、治疗2个月后,参照PASI进行评估,以判定临床疗效.治疗前、治疗1个月后、治疗2个月后,应用皮肤病生活质量指数(dermatology life quality index,DLQD)[9]评价生活质量.采用酶联免疫吸附法检测白细胞介素-1(interleukin-1,IL-1)、IL-1 受体拮抗剂(IL-1 receptor antagonist,IL-1 RA)、IL-17、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、血管内皮生长因子(vascular endothelial growth factor,VEGF)水平.并采用广义估计方程(generalized estimating equation,GEE)模型统计分析两组间IL-1、IL-1RA与PASI的差异.结果 治疗组患者治疗1个月后和治疗2个月后PASI评分、IL-1、IL-17、TNF-α和VEGF水平均低于对照组(P<0.05),IL-1RA水平均高于对照组(P<0.05).治疗2个月后,治疗组患者的DLQD评分、皮肤瘙痒程度评分、不良反应(adverse reactions,ARS)、复发率均低于对照组(P<0.05).治疗2个月后,治疗组临床总有效率高于对照组(P<0.05).GEE分析结果显示,治疗组患者IL-1、IL-1RA及PASI的改善情况均显著优于对照组(P<0.05).结论 采用308 nm准分子激光联合司库奇尤单抗治疗PS的临床效果显著,可有效缓解患者的临床症状,减少皮损面积,减轻炎症反应,提高生活质量,降低ARS及复发率,安全可靠.
Evaluation Joint Effect of 308 nm Excimer Light and Secukinumab on IL-1 and IL-1 RA of Psoriasis Patients Based on Generalized Estimating Equations
Objective To evaluate the joint effect of 308nm excimer light and secukinumab on the aesthetic observation of psoriasis(PS)and the effect on the interleukin-1(IL-1)and IL-1 receptor antagonist(IL-1RA)of psoriasis patients based on generalized estimating equations(GEE).Methods The clinical data of the PS patients(n=120)treated between Jun.2021 and Oct.2023 were retrospective analyzed,and the patients were divided into a treatment group(n=64)and a control group(n=56)by treating methods.The patients in the treatment group were given combined treatment of 308 nm excimer light and secukinumab,and those in the control group only given the treatment of secukinumab.The clinical data of the patients of both groups were collected and compared for analysis.One month and two months after the treatment,GEE was used to evaluate the improvement of IL-1、IL-1RA and area and psoriasis severity index(PASI)respectively for the patients of both groups.Results One month and two months after the treatment,compared with those in the control group,the patients in the treatment group had lower PASI scores and lower levels of IL-1,IL-17,tumor necrosis factor-α(TNF-α)and vascular endothelial growth factor(VEGF)and higher IL-1RA levels(P<0.05).Two months after the treatment,compared with those in the control group,the patients in the treatment group had lower DLQD scores,skin itching levels,adverse reactions(ARS)incurrence and recurrence rates(P<0.05)and higher overall clinical efficacy(P<0.05).The GEE analysis results showed that the improvement of IL-1,IL-1RA and PASI in the treatment group was greater than that in the control group(P<0.05).Conclusions Being a safe,reliable and effective treatment for psoriasis,the combination of 308 nm excimer light and secukinumab will effectively alleviate patients'clinical symptoms,reduce skin lesion areas,alleviate inflammatory reactions,improve patients'quality of life and reduce the incidence of ARS and recurrence of psoriasis.

SecukinumabExcimer lightPsoriasisGeneralized estimating equations

张蓓、沈娟、郄永涛

展开 >

河北省皮肤病防治院药剂科(保定市,071000)

河北省皮肤病防治院检验科(保定市,071000)

河北省皮肤病防治院中医皮肤科(保定市,071000)

司库奇尤单抗 准分子光 银屑病 广义估计方程

2024

中国激光医学杂志
中国光学学会

中国激光医学杂志

CSTPCD
影响因子:0.677
ISSN:1003-9430
年,卷(期):2024.33(6)